Table 4.
Predictors of liver impairment and ALT > 165 IU/l occurring on or after first day of statin administration
| Variable | Univariable analyses | Multivariable analyses | ||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% CI | P value | Odds ratio | 95% CI | P value | |
| Liver impairment (n = 1,319)a | ||||||
| Statin versus no statin | 1.41 | 0.89 to 2.24 | 0.14 | 1.08 | 0.66 to 1.77 | 0.75 |
| Ageb | 1.005 | 0.99 to 1.02 | 0.36 | 0.99 | 0.98 to 1.004 | 0.21 |
| Admission APACHE II scoreb | 1.06 | 1.03 to 1.09 | < 0.0001 | 1.05 | 1.02 to 1.08 | 0.0007 |
| APACHE II admission category (reference level: respiratory) | 0.017 | 0.062 | ||||
| Cardiovascular | 1.57 | 1.04 to 2.39 | 0.033 | 1.43 | 0.93 to 2.19 | 0.099 |
| Gastrointestinal | 1.46 | 0.76 to 2.80 | 0.25 | 1.67 | 0.86 to 3.25 | 0.13 |
| Neurological | 0.58 | 0.28 to 1.19 | 0.14 | 0.62 | 0.30 to 1.30 | 0.21 |
| Gender (female) | 0.62 | 0.41 to 0.94 | 0.028 | 0.65 | 0.42 to 0.99 | 0.043 |
| Baseline hepatic SOFA | 0.065 | 0.011 | ||||
| 1 versus 0 | 0.58 | 0.36 to 0.92 | 0.02 | 0.49 | 0.30 to 0.79 | 0.0032 |
| 2 versus 0 | 0.85 | 0.49 to 1.46 | 0.56 | 0.67 | 0.38 to 1.18 | 0.17 |
| Total baseline nonhepatic SOFAb | 1.36 | 1.19 to 1.55 | < 0.0001 | 1.29 | 1.11 to 1.50 | 0.0009 |
| ALT (n = 1,229)c | ||||||
| Statin versus no statin | 2.22 | 1.37 to 3.60 | 0.001 | 2.25 | 1.32 to 3.84 | 0.003 |
| Ageb | 1.00 | 0.98 to 1.01 | 0.46 | 0.99 | 0.97 to 1.002 | 0.091 |
| Admission APACHE II scoreb | 1.05 | 1.01 to 1.08 | 0.005 | 1.04 | 1.01 to 1.08 | 0.016 |
| APACHE II admission category (reference level: respiratory) | 0.054 | 0.12 | ||||
| Cardiovascular | 1.47 | 0.89 to 2.41 | 0.13 | 1.16 | 0.70 to 1.94 | 0.57 |
| Gastrointestinal | 0.30 | 0.072 to 1.25 | 0.098 | 0.40 | 0.094 to 1.70 | 0.21 |
| Neurological | 1.63 | 0.90 to 2.94 | 0.11 | 1.80 | 0.97 to 3.34 | 0.063 |
| Gender (female) | 0.77 | 0.48 to 1.22 | 0.26 | 0.90 | 0.56 to 1.45 | 0.67 |
| Baseline ALTd | 1.14 | 1.08 to 1.20 | < 0.0001 | 1.11 | 1.05 to 1.18 | 0.0001 |
| Total baseline SOFAb | 1.10 | 0.96 to 1.26 | 0.17 | 1.08 | 0.94 to 1.25 | 0.26 |
Predictors of liver impairment and alanine transferase (ALT) > 165 IU/l occurring on or after the first day of statin administration. APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; SOFA, Sequential Organ Failure Assessment. aSeventy-eight patients were excluded from the model: 61 patients with missing data on at least one of the variables included in the model, and 17 patients with the APACHE II admission category of metabolic, of whom only one was in the statin group. bOdds ratios per one-unit increase. cA total of 168 patients were excluded from the model: 77 patients with baseline ALT > 165 IU/l, 75 with missing data for at least one of the variables included in the model, and 16 patients with the APACHE II admission category of metabolic, of whom only one was in the statin group. dOdds ratio per 10-unit increase.